Day One Biopharmaceuticals (DAWN) Financials

$6.98 -0.03 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$7.07 +0.09 (+1.35%)

As of 05:31 PM Eastern

Annual Income Statements for Day One Biopharmaceuticals

This table shows Day One Biopharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-95	-189	-142
Consolidated Net Income / (Loss)	-95	-189	-142
Net Income / (Loss) Continuing Operations	-95	-189	-142
Total Pre-Tax Income	-88	-189	-142
Total Operating Income	-217	-206	-147
Total Gross Profit	126	0.00	0.00
Total Revenue	131	0.00	0.00
Operating Revenue	131	0.00	0.00
Total Cost of Revenue	5.28	0.00	0.00
Operating Cost of Revenue	5.28	0.00	0.00
Total Operating Expenses	343	206	147
Selling, General & Admin Expense	115	76	61
Research & Development Expense	228	131	86
Total Other Income / (Expense), net	129	17	4.73
Interest & Investment Income	128	17	4.75
Other Income / (Expense), net	1.22	-	-0.02
Income Tax Expense	7.14	0.00	0.00
Basic Earnings per Share	($1.02)	($2.37)	($2.17)
Weighted Average Basic Shares Outstanding	93.23M	79.77M	65.47M
Diluted Earnings per Share	($1.02)	($2.37)	($2.17)
Weighted Average Diluted Shares Outstanding	93.23M	79.77M	65.47M
Weighted Average Basic & Diluted Shares Outstanding	101.35M	87.38M	73.59M

This table shows Day One Biopharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-99	73	-7.26	-62	-55	-46	-46	-42	-40	-38
Consolidated Net Income / (Loss)	-66	37	-4.41	-62	-55	-46	-46	-42	-40	-38
Net Income / (Loss) Continuing Operations	-66	37	-4.41	-62	-55	-46	-46	-42	-40	-38
Total Pre-Tax Income	-59	36	-2.86	-62	-55	-46	-46	-42	-40	-38
Total Operating Income	-65	30	-115	-67	-60	-51	-49	-46	-43	-40
Total Gross Profit	26	92	7.49	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	29	94	8.19	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	2.98	1.59	0.71	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	92	63	122	67	60	51	49	46	43	40
Selling, General & Admin Expense	30	29	30	27	22	18	17	18	17	18
Research & Development Expense	62	34	92	40	37	33	32	28	26	22
Total Other Income / (Expense), net	6.09	6.52	112	4.36	5.05	5.29	3.39	3.46	2.63	1.90
Interest & Investment Income	6.05	5.32	112	4.37	5.02	5.29	3.41	3.47	2.66	1.90
Other Income / (Expense), net	0.04	1.20	-0.01	-0.01	-	-0.00	-0.02	-0.00	-0.03	0.01
Basic Earnings per Share	($0.63)	$0.38	($0.05)	($0.72)	($0.63)	($0.54)	($0.61)	($0.59)	($0.56)	($0.53)
Weighted Average Basic Shares Outstanding	93.23M	96.62M	87.12M	86.68M	79.77M	85.95M	74.96M	71.97M	65.47M	71.01M
Diluted Earnings per Share	($0.63)	$0.38	($0.05)	($0.72)	($0.63)	($0.54)	($0.61)	($0.59)	($0.56)	($0.53)
Weighted Average Diluted Shares Outstanding	93.23M	96.94M	87.12M	86.68M	79.77M	85.95M	74.96M	71.97M	65.47M	71.01M
Weighted Average Basic & Diluted Shares Outstanding	101.35M	100.85M	87.76M	87.39M	87.38M	87.04M	86.97M	73.57M	73.59M	73.55M

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-106	146	-199
Net Cash From Operating Activities	-78	-147	-110
Net Cash From Continuing Operating Activities	-78	-147	-110
Net Income / (Loss) Continuing Operations	-95	-189	-142
Consolidated Net Income / (Loss)	-95	-189	-142
Depreciation Expense	0.09	0.04	0.06
Amortization Expense	-4.45	-9.73	-1.56
Non-Cash Adjustments To Reconcile Net Income	-4.74	42	27
Changes in Operating Assets and Liabilities, net	26	9.42	6.56
Net Cash From Investing Activities	-231	128	-255
Net Cash From Continuing Investing Activities	-231	128	-255
Purchase of Property, Plant & Equipment	-2.17	-0.22	-0.03
Acquisitions	-17	0.00	0.00
Purchase of Investments	-659	-444	-394
Sale of Property, Plant & Equipment	108	0.00	0.00
Sale and/or Maturity of Investments	394	575	139
Other Investing Activities, net	-55	-3.00	0.00
Net Cash From Financing Activities	203	164	166
Net Cash From Continuing Financing Activities	203	164	166
Issuance of Common Equity	201	163	162
Other Financing Activities, net	2.27	1.34	3.65
Cash Income Taxes Paid	1.90	0.00	0.00

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-298	183	-31	40	-10	52	140	-36	-36	-268
Net Cash From Operating Activities	-30	51	-49	-50	-41	-37	-42	-26	-35	-23
Net Cash From Continuing Operating Activities	-30	51	-49	-50	-41	-37	-42	-26	-35	-23
Net Income / (Loss) Continuing Operations	-66	37	-4.41	-62	-55	-46	-46	-42	-40	-38
Consolidated Net Income / (Loss)	-66	37	-4.41	-62	-55	-46	-46	-42	-40	-38
Depreciation Expense	0.04	0.02	0.02	0.02	0.01	0.01	0.01	0.01	0.02	0.04
Amortization Expense	-2.10	-0.65	-0.50	-1.20	-1.49	-2.56	-5.17	-0.52	-1.87	0.13
Non-Cash Adjustments To Reconcile Net Income	11	67	-95	13	11	12	9.48	9.45	7.86	7.55
Changes in Operating Assets and Liabilities, net	27	-52	51	1.22	3.50	-0.68	-0.88	7.47	-1.22	6.87
Net Cash From Investing Activities	-270	-68	17	89	30	89	20	-11	-2.21	-247
Net Cash From Continuing Investing Activities	-270	-68	17	89	30	89	20	-11	-2.21	-247
Purchase of Property, Plant & Equipment	-1.42	-0.72	-0.03	0.00	-0.01	-0.04	-0.15	-0.03	-	-0.00
Purchase of Investments	-275	-215	-122	-47	-99	-80	-105	-160	-121	-267
Sale and/or Maturity of Investments	7.00	203	48	136	130	172	125	149	119	20
Net Cash From Financing Activities	1.85	200	1.30	0.05	0.60	0.12	162	1.18	1.92	2.05
Net Cash From Continuing Financing Activities	1.85	200	1.30	0.05	0.60	0.12	162	1.18	1.92	2.37
Issuance of Common Equity	0.93	199	0.97	0.00	0.60	-	162	0.00	0.32	0.32
Other Financing Activities, net	0.92	0.98	0.32	0.05	-	0.12	0.04	1.18	1.60	2.05
Cash Income Taxes Paid	1.02	-	-	-	-	-	-	-	-	-

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	583	376	349
Total Current Assets	562	375	348
Cash & Equivalents	125	231	85
Short-Term Investments	407	136	257
Accounts Receivable	14	0.00	-
Inventories, net	3.32	0.00	-
Prepaid Expenses	13	8.93	5.61
Plant, Property, & Equipment, net	2.29	0.21	0.02
Total Noncurrent Assets	18	0.57	1.17
Intangible Assets	16	0.00	-
Other Noncurrent Operating Assets	2.54	0.57	1.17
Total Liabilities & Shareholders' Equity	583	376	349
Total Liabilities	80	30	17
Total Current Liabilities	73	30	17
Accounts Payable	3.26	2.58	0.26
Accrued Expenses	69	27	16
Current Deferred Revenue	1.55	0.00	-
Other Current Liabilities	0.01	0.41	0.41
Total Noncurrent Liabilities	6.59	0.00	0.41
Noncurrent Deferred Revenue	3.23	0.00	-
Other Noncurrent Operating Liabilities	3.35	0.00	0.41
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	503	347	332
Total Preferred & Common Equity	503	347	332
Total Common Equity	503	347	332
Common Stock	1,057	805	602
Retained Earnings	-554	-459	-270
Accumulated Other Comprehensive Income / (Loss)	0.08	0.01	-0.07

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	601	400	327	414	451	324	382
Total Current Assets	581	383	326	413	450	645	381
Cash & Equivalents	423	240	270	241	189	49	121
Short-Term Investments	136	122	48	164	254	269	253
Accounts Receivable	8.70	9.14	-	-	-	-	-
Inventories, net	2.74	0.15	-	-	-	-	-
Prepaid Expenses	11	12	8.09	7.75	6.90	4.21	6.17
Plant, Property, & Equipment, net	0.90	0.20	0.19	0.21	0.18	0.07	0.04
Total Noncurrent Assets	19	17	0.26	0.68	0.79	1.10	1.31
Intangible Assets	16	17	-	-	-	-	-
Other Noncurrent Operating Assets	2.69	0.16	0.26	0.68	0.79	1.10	1.31
Total Liabilities & Shareholders' Equity	601	400	327	414	451	324	382
Total Liabilities	45	94	30	25	25	23	19
Total Current Liabilities	40	94	30	24	25	23	18
Accounts Payable	3.02	6.44	4.78	3.39	4.57	4.66	3.97
Accrued Expenses	35	87	25	21	20	18	14
Current Deferred Revenue	1.46	-	-	-	-	-	-
Other Current Liabilities	0.08	0.19	0.30	0.44	0.43	0.42	0.46
Total Noncurrent Liabilities	5.60	0.00	0.00	0.08	0.19	0.30	0.51
Noncurrent Deferred Revenue	3.06	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	2.54	-	-	0.08	0.19	0.30	0.51
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	555	307	297	390	426	300	363
Total Preferred & Common Equity	555	307	297	390	426	300	363
Total Common Equity	555	307	297	390	426	300	363
Common Stock	1,044	832	818	794	784	612	593
Retained Earnings	-488	-525	-521	-404	-358	-312	-230
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.02	-0.01	-0.01	-0.01	0.07	-0.39

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-2.16%	-45.36%	-104.56%
EBIT Growth	-4.85%	-40.25%	-101.94%
NOPAT Growth	-5.44%	-40.27%	-101.96%
Net Income Growth	49.45%	-32.87%	-95.43%
EPS Growth	56.96%	-9.22%	53.03%
Operating Cash Flow Growth	46.81%	-33.66%	-126.36%
Free Cash Flow Firm Growth	-6.13%	-40.37%	31.39%
Invested Capital Growth	-46.26%	-93.62%	-207.21%
Revenue Q/Q Growth	28.65%	0.00%	0.00%
EBITDA Q/Q Growth	-8.05%	-9.31%	-18.06%
EBIT Q/Q Growth	-2.74%	-8.83%	-16.50%
NOPAT Q/Q Growth	-2.75%	-8.86%	-16.46%
Net Income Q/Q Growth	-13.29%	-8.25%	-14.65%
EPS Q/Q Growth	0.00%	-3.04%	-226.16%
Operating Cash Flow Q/Q Growth	12.70%	-4.31%	-25.24%
Free Cash Flow Firm Q/Q Growth	11.23%	-5.33%	0.00%
Invested Capital Q/Q Growth	-892.09%	-24.49%	9.19%
Profitability Metrics	-	-	-
Gross Margin	95.98%	0.00%	0.00%
EBITDA Margin	-168.05%	0.00%	0.00%
Operating Margin	-165.65%	0.00%	0.00%
EBIT Margin	-164.72%	0.00%	0.00%
Profit (Net Income) Margin	-72.81%	0.00%	0.00%
Tax Burden Percent	108.09%	100.00%	100.00%
Interest Burden Percent	40.89%	91.68%	96.77%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-22.49%	-55.68%	-46.37%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-45.07%	0.00%	0.00%
Return on Assets (ROA)	-19.92%	0.00%	0.00%
Return on Common Equity (ROCE)	-22.49%	-55.68%	-46.37%
Return on Equity Simple (ROE_SIMPLE)	-18.99%	-54.52%	-42.82%
Net Operating Profit after Tax (NOPAT)	-152	-144	-103
NOPAT Margin	-115.96%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	12.60%	-12.61%	-12.56%
Return On Investment Capital (ROIC_SIMPLE)	-30.25%	-41.62%	-30.97%
Cost of Revenue to Revenue	4.02%	0.00%	0.00%
SG&A Expenses to Revenue	88.02%	0.00%	0.00%
R&D to Revenue	173.61%	0.00%	0.00%
Operating Expenses to Revenue	261.63%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-216	-206	-147
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-220	-216	-148
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.54	3.67	4.77
Price to Tangible Book Value (P/TBV)	2.62	3.67	4.77
Price to Revenue (P/Rev)	9.74	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.69	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.06	-1.04	-1.02
Leverage Ratio	1.13	1.07	1.04
Compound Leverage Factor	0.46	0.98	1.01
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	8.26	23.43	54.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.66	12.72	20.94
Quick Ratio	7.43	12.42	20.60
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-143	-135	-96
Operating Cash Flow to CapEx	0.00%	-65,559.38%	-422,592.31%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.27	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	105.22	0.00	0.00
Accounts Payable Turnover	1.81	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	201.83	0.00	0.00
Cash Conversion Cycle (CCC)	-201.83	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-29	-20	-10
Invested Capital Turnover	-5.38	0.00	0.00
Increase / (Decrease) in Invested Capital	-9.16	-9.58	-6.90
Enterprise Value (EV)	746	904	1,241
Market Capitalization	1,278	1,271	1,583
Book Value per Share	$4.99	$3.98	$4.51
Tangible Book Value per Share	$4.83	$3.98	$4.51
Total Capital	503	347	332
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-532	-366	-342
Capital Expenditures (CapEx)	-106	0.22	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-43	-21	-11
Debt-free Net Working Capital (DFNWC)	489	346	331
Net Working Capital (NWC)	489	346	331
Net Nonoperating Expense (NNE)	-57	45	39
Net Nonoperating Obligations (NNO)	-532	-366	-342
Total Depreciation and Amortization (D&A)	-4.36	-9.70	-1.50
Debt-free, Cash-free Net Working Capital to Revenue	-32.66%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	372.73%	0.00%	0.00%
Net Working Capital to Revenue	372.73%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.02)	($2.37)	($2.17)
Adjusted Weighted Average Basic Shares Outstanding	93.23M	79.77M	65.47M
Adjusted Diluted Earnings per Share	($1.02)	($2.37)	($2.17)
Adjusted Weighted Average Diluted Shares Outstanding	93.23M	79.77M	65.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	101.35M	87.38M	73.59M
Normalized Net Operating Profit after Tax (NOPAT)	-152	-144	-103
Normalized NOPAT Margin	-115.96%	0.00%	0.00%
Pre Tax Income Margin	-67.36%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-10.44%	155.94%	-111.82%	-46.55%	-36.69%	-36.59%	-48.79%	-67.42%	-103.62%	-106.03%
EBIT Growth	-9.70%	159.94%	-133.04%	-45.61%	-39.16%	-29.61%	-34.18%	-65.26%	-94.72%	-106.35%
NOPAT Growth	-9.77%	184.32%	-133.09%	-45.60%	-39.24%	-29.57%	-34.14%	-65.26%	-36.14%	-106.33%
Net Income Growth	-20.55%	180.25%	90.39%	-47.22%	-35.91%	-22.11%	-25.55%	-52.78%	-82.81%	-96.44%
EPS Growth	0.00%	170.37%	91.80%	-22.03%	-12.50%	-1.89%	-1.67%	-22.92%	-116.82%	-60.61%
Operating Cash Flow Growth	27.47%	236.93%	-15.78%	-91.38%	-17.17%	-59.66%	-42.45%	-20.51%	-168.13%	-89.95%
Free Cash Flow Firm Growth	-13.98%	155.38%	-91.66%	182.15%	-39.38%	-95.85%	-11.06%	-1,985.54%	0.00%	-14.53%
Invested Capital Growth	-46.26%	81.65%	-228.33%	-106.99%	-93.62%	-41.24%	-297.54%	9,838.62%	-207.21%	-2,300.20%
Revenue Q/Q Growth	-68.85%	1,044.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-323.02%	126.19%	-69.68%	-14.34%	-12.97%	0.83%	-17.40%	-8.88%	-12.89%	-8.03%
EBIT Q/Q Growth	-311.76%	126.85%	-71.94%	-12.16%	-15.70%	-4.41%	-7.44%	-7.22%	-7.76%	-8.09%
NOPAT Q/Q Growth	-250.64%	137.78%	-71.95%	-12.18%	-15.71%	-4.43%	-7.41%	-7.28%	-7.67%	-8.12%
Net Income Q/Q Growth	-277.43%	940.41%	92.94%	-14.49%	-18.12%	-0.63%	-8.19%	-5.69%	-6.12%	-3.46%
EPS Q/Q Growth	-265.79%	860.00%	93.06%	-14.29%	-16.67%	11.48%	-3.39%	-5.36%	-5.66%	11.67%
Operating Cash Flow Q/Q Growth	-159.13%	203.31%	1.21%	-20.20%	-11.62%	12.65%	-63.29%	26.41%	-52.11%	22.07%
Free Cash Flow Firm Q/Q Growth	-310.56%	141.41%	-115.02%	970.17%	-2.31%	-43.31%	93.56%	-1,376.32%	-43.77%	18.73%
Invested Capital Q/Q Growth	-892.09%	94.72%	-159.34%	-7.56%	-24.49%	5.45%	-105.52%	3,077.75%	9.19%	-166.12%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.79%	98.30%	91.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-230.61%	32.21%	-1,407.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-223.68%	31.61%	-1,401.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-223.54%	32.88%	-1,401.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-224.99%	39.50%	-53.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	110.93%	102.44%	154.36%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	90.73%	117.26%	2.49%	93.46%	91.59%	89.71%	93.09%	92.44%	93.78%	95.23%
Effective Tax Rate	0.00%	-2.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-22.49%	-17.84%	-45.71%	-69.97%	-55.68%	-46.37%	-40.69%	-56.01%	-46.37%	-37.54%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-138.95%	0.00%	0.00%
Operating Return on Assets (OROA)	-61.16%	6.61%	-26.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-61.55%	7.94%	-1.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-22.49%	-17.84%	-45.71%	-69.97%	-55.68%	-46.37%	-40.69%	-56.01%	-46.37%	-37.54%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-15.18%	-54.60%	-70.39%	0.00%	-44.79%	-39.00%	-52.20%	0.00%	-34.16%
Net Operating Profit after Tax (NOPAT)	-46	30	-80	-47	-42	-36	-34	-32	-30	-28
NOPAT Margin	-156.57%	32.38%	-981.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.45%	1.39%	18.87%	-9.99%	-3.63%	-2.60%	-2.72%	-7.96%	-3.25%	-2.98%
Return On Investment Capital (ROIC_SIMPLE)	-9.10%	-	-	-	-12.02%	-	-	-	-9.01%	-
Cost of Revenue to Revenue	10.21%	1.70%	8.63%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	101.80%	30.90%	368.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	211.66%	35.80%	1,124.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	313.47%	66.70%	1,492.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-65	31	-115	-67	-60	-51	-49	-46	-43	-40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-67	30	-115	-68	-61	-54	-54	-46	-45	-40
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.54	2.20	3.93	4.84	3.67	2.74	2.06	3.28	4.77	4.05
Price to Tangible Book Value (P/TBV)	2.62	2.27	4.15	4.84	3.67	2.74	2.06	3.28	4.77	4.05
Price to Revenue (P/Rev)	9.74	11.99	147.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.19	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.69	6.51	102.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	6.70	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.06	-1.02	-1.10	-0.53	-1.04	-1.04	-1.03	-0.46	-1.02	-1.02
Leverage Ratio	1.13	1.07	1.16	1.09	1.07	1.06	1.05	1.06	1.04	1.04
Compound Leverage Factor	1.02	1.26	0.03	1.02	0.98	0.95	0.97	0.98	0.98	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.11	16.46	5.82	27.09	24.71	25.43	21.00	25.99	55.44	46.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.66	14.62	4.09	10.93	12.72	16.89	18.35	28.22	20.94	20.83
Quick Ratio	7.43	14.27	3.96	10.66	12.42	16.57	18.07	13.93	20.60	20.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-37	17	-42	279	-32	-31	-22	-340	-23	-16
Operating Cash Flow to CapEx	-2,114.73%	7,010.08%	-188,957.69%	0.00%	-517,150.00%	-90,400.00%	-28,477.85%	-99,942.31%	0.00%	-580,350.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.27	0.20	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	105.22	182.55	43.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	1.81	0.72	0.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	201.83	509.12	2,841.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-201.83	-509.12	-2,841.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-29	-2.92	-55	-21	-20	-16	-17	305	-10	-11
Invested Capital Turnover	-5.38	-10.83	-0.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-9.16	13	-38	-326	-9.58	-4.65	-13	308	-6.90	-12
Enterprise Value (EV)	746	664	842	1,120	904	662	436	666	1,241	1,097
Market Capitalization	1,278	1,223	1,204	1,438	1,271	1,067	878	984	1,583	1,471
Book Value per Share	$4.99	$6.33	$3.51	$3.42	$3.98	$4.48	$5.79	$4.08	$4.51	$4.94
Tangible Book Value per Share	$4.83	$6.14	$3.32	$3.42	$3.98	$4.48	$5.79	$4.08	$4.51	$4.94
Total Capital	503	555	307	297	347	390	426	300	332	363
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-532	-558	-362	-318	-366	-406	-443	-318	-342	-374
Capital Expenditures (CapEx)	1.42	0.72	0.03	0.00	0.01	0.04	0.15	0.03	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-43	-17	-72	-22	-21	-17	-18	304	-11	-12
Debt-free Net Working Capital (DFNWC)	489	541	289	296	346	389	425	622	331	362
Net Working Capital (NWC)	489	541	289	296	346	389	425	622	331	362
Net Nonoperating Expense (NNE)	20	-6.68	-76	16	13	10	11	10	10	10
Net Nonoperating Obligations (NNO)	-532	-558	-362	-318	-366	-406	-443	4.21	-342	-374
Total Depreciation and Amortization (D&A)	-2.06	-0.63	-0.49	-1.18	-1.47	-2.55	-5.17	-0.51	-1.85	0.17
Debt-free, Cash-free Net Working Capital to Revenue	-32.66%	-16.80%	-883.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	372.73%	530.88%	3,533.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	372.73%	530.88%	3,533.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.63)	$0.38	($0.05)	($0.72)	($0.63)	($0.54)	($0.61)	($0.59)	($0.56)	($0.53)
Adjusted Weighted Average Basic Shares Outstanding	93.23M	96.62M	87.12M	86.68M	79.77M	85.95M	74.96M	71.97M	65.47M	71.01M
Adjusted Diluted Earnings per Share	($0.63)	$0.38	($0.05)	($0.72)	($0.63)	($0.54)	($0.61)	($0.59)	($0.56)	($0.53)
Adjusted Weighted Average Diluted Shares Outstanding	93.23M	96.94M	87.12M	86.68M	79.77M	85.95M	74.96M	71.97M	65.47M	71.01M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	101.35M	100.85M	87.76M	87.39M	87.38M	87.04M	86.97M	73.57M	73.59M	73.55M
Normalized Net Operating Profit after Tax (NOPAT)	-46	21	-80	-47	-42	-36	-34	-32	-30	-28
Normalized NOPAT Margin	-156.57%	22.13%	-981.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-202.82%	38.56%	-34.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

When does Day One Biopharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Day One Biopharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Day One Biopharmaceuticals' net income changed over the last 2 years?

Day One Biopharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$95.50 million in 2024, falling from -$142.18 million in 2022. The previous period was -$188.92 million in 2023. See Day One Biopharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Day One Biopharmaceuticals's operating income?

Day One Biopharmaceuticals's total operating income in 2024 was -$217.27 million, based on the following breakdown:

Total Gross Profit: $125.88 million
Total Operating Expenses: $343.15 million

How has Day One Biopharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Day One Biopharmaceuticals' total revenue changed from $0.00 in 2022 to $131.16 million in 2024, a change of 13,116,100,000.0%.

How much debt does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals' total liabilities were at $80.04 million at the end of 2024, a 171.2% increase from 2023, and a 370.2% increase since 2022.

How much cash does Day One Biopharmaceuticals have?

In the past 2 years, Day One Biopharmaceuticals' cash and equivalents has ranged from $85.26 million in 2022 to $230.78 million in 2023, and is currently $124.97 million as of their latest financial filing in 2024.

How has Day One Biopharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Day One Biopharmaceuticals' book value per share changed from 4.51 in 2022 to 4.99 in 2024, a change of 10.4%.

Related Companies

This page (NASDAQ:DAWN) was last updated on 6/3/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Day One Biopharmaceuticals (DAWN) Financials

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Day One Biopharmaceuticals (DAWN) Financials

Annual Income Statements for Day One Biopharmaceuticals

Quarterly Income Statements for Day One Biopharmaceuticals

Annual Cash Flow Statements for Day One Biopharmaceuticals

Quarterly Cash Flow Statements for Day One Biopharmaceuticals

Annual Balance Sheets for Day One Biopharmaceuticals

Quarterly Balance Sheets for Day One Biopharmaceuticals

Annual Metrics And Ratios for Day One Biopharmaceuticals

Quarterly Metrics And Ratios for Day One Biopharmaceuticals

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools